Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

• Үндсэн зохиолчид: Kerui Xu (Зохиогч), Li-Ming Liu (Зохиогч), Paraskevi A. Farazi (Зохиогч), Hongmei Wang (Зохиогч), Fedja A Rochling (Зохиогч), Shinobu Watanabe-Galloway (Зохиогч), Jian-Jun Zhang (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background: Globally, of the 248 million people chronically infected with the hepatitis B virus (HBV), 74 million reside in China. Five oral nucleot(s)ide analogs (NUCs) have been approved for the treatment of chronic hepatitis B (CHB) in China. Objectives: The aims of this study were to determine r...